MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study

Clinical efficacy of redifferentiation therapy with histone deacetylase inhibitor (HDACi) for lethal radioiodine-refractory papillary thyroid cancer (RR-PTC) is urgently needed to be improved. Given that the impairment of histone acetylation is a mechanism in BRAF(V600E)-mitogen-activated protein ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Hao, Cheng, Lingxiao, Jin, Yuchen, Cheng, Lin, Liu, Min, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389779/
https://www.ncbi.nlm.nih.gov/pubmed/30847387
http://dx.doi.org/10.1016/j.omto.2019.01.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389779/
https://www.ncbi.nlm.nih.gov/pubmed/30847387
http://dx.doi.org/10.1016/j.omto.2019.01.007

Ejemplares similares